Oslo, June 25th, 2024. The Division of Clinical Neuroscience at Oslo University Hospital and the Swedish drug development company TikoMed have recently signed a research collaboration agreement. Common ambition for the parties is for their collaboration to lead to more knowledge and better treatment options for patients diagnosed with Amyotrophic Lateral Sclerosis – ALS.
TikoMed has previously completed and reported on two successful phase 2a clinical studies in ALS, one at the Sahlgrenska University Hospital in Sweden and one at the University of Birmingham in the UK, both with promising results.1,2 The trial data establish the safety and tolerability of ILB® in people with ALS, while also indicating its future potential to be the first disease-modifying drug to treat both familial and sporadic ALS with minimal side-effects.
TikoMed’s Scientific Advisor, Professor Ann Logan, Honorary Professor of Regenerative Medicine at the University of Warwick, states “We are very excited about the clinical potential for ILB®, which may prove to be a game changing treatment for many devastating neuro-degenerative diseases.”
For more information:
TikoMed, Christian Treschow, Chairman,
TikoMed, Lars Bruce, responsible for of the ILB® program
To the editors
TikoMed in brief:
TikoMed is a Swedish, private company founded in 2002 by the Bruce family. Lars Bruce, who is the lead of the ILB® program, is an entrepreneur and inventor with several commercial inventions in mechanics, metallurgy and medicine.
Inventor Lars Bruce refers to the drug, called ILB®, as the discovery of the ‘Missing Link’ that orchestrates tissue repair signals. The ILB® treatment switches on the natural repair system of the body and is a drug addressing neuro-degenerative and neuro-inflammatory processes through endogenous activation of a repertoire of growth factors.